400 S. El Camino Real, 12th Floor
Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling's unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates-of-return for both its entrepreneurs and investors.
Sanderling emphasizes early-stage financing and active management of its portfolio companies. Sanderling and its principals play an active role in new ventures by providing seed and early-stage funding, contributing management leadership and administrative support, developing cost-control strategies to extend available dollars, supplying technical and regulatory expertise where needed, and offering the insight and perspective of those who have "done it before." The Partnership has sufficient capital to support the companies in later-stage financing, protecting its investments from excessive dilution.
Sanderling focuses on substantial new biomedical market opportunities including emerging technology in the following areas: biotechnology, therapeutics and pharmaceuticals, drug delivery, medical devices and instrumentation, imaging and diagnostics, medical informatics, and health care services.
Paulette Taylor, General Counsel
Last Updated: 08-15-03